Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.77 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1724253 | 1.00 | NR1H4 (0.77) | NR1H4GABRA1GABRA2PTGS2CYP3A4 | |
| SCHEMBL12012950 | 0.98 | NR1H4 (0.74) | NR1H4GABRA1GABRA2CYP3A4CYP2D6 | |
| SCHEMBL12394132 | 0.86 | NR1H4 (0.57) | NR1H4CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12394127 | 0.85 | NR1H4 (0.56) | NR1H4GABRA1GABRA2CYP3A4CYP2D6 | |
| SCHEMBL2382062 | 0.85 | NR1H4 (0.97) | NR1H4GABRA1GABRA2CYP3A4CYP2D6 | |
| SCHEMBL3147950 | 0.82 | NR1H4 (0.53) | NR1H4GABRA1GABRA2PTGS2CYP3A4 | |
| SCHEMBL1712446 | 0.82 | NR1H4 (0.69) | NR1H4GABRA1GABRA2 | |
| SCHEMBL2381699 | 0.82 | NR1H4 (0.69) | NR1H4GABRA1GABRA2 | |
| SCHEMBL1727850 | 0.80 | NR1H4 (0.51) | NR1H4GABRA1GABRA2PTGS2 | |
| SCHEMBL2382373 | 0.80 | NR1H4 (0.67) | NR1H4GABRA1GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252826-B2 | Cyclopentyl- and cycloheptylpyrazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-08-28 | — | — | US | claimed |
| US-20110237628-A1 | CYCLOPENTYL- AND CYCLOHEPTYLPYRAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | US | claimed |
| US-20220016136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | VIKING THERAPEUTICS, INC. | 2022-01-20 | — | — | US | disclosed |
| EP-2550254-A1 | CYCLOPENTYL - AND CYCLOHEPTYLPYRAZOLES AS FXR MODULATORS | F. Hoffmann-La Roche AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| US-8252826-B2 | Cyclopentyl- and cycloheptylpyrazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252826-B2 | Cyclopentyl- and cycloheptylpyrazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20110237628-A1 | CYCLOPENTYL- AND CYCLOHEPTYLPYRAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | US | disclosed |
| US-20110237628-A1 | CYCLOPENTYL- AND CYCLOHEPTYLPYRAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | US | disclosed |
| WO-2011117163-A1 | CYCLOPENTYL - AND CYCLOHEPTYLPYRAZOLES AS FXR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011117163-A1 | CYCLOPENTYL - AND CYCLOHEPTYLPYRAZOLES AS FXR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | FABP1, SLC10A1, TSHR | NR1H4 11/4885GABRA1 888/4885GABRA2 795/4885 |
| US-20110237628-A1 | CYCLOPENTYL- AND CYCLOHEPTYLPYRAZOLES | CYP1B1, CYP1A1, CYP4F3 | NR1H4 644/4885GABRA1 366/4885GABRA2 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.